NANETS Regional NET Education: The Multidisciplinary minneapolis 1Management of NET Disease

CME/CE Certified Activity

Saturday, June 29, 2019
7:30am – 4:20pm 


Grand Hotel Minneapolis

615 Second Avenue South

Minneapolis, MN 55402


Jointly Provided by Mayo Clinic, the University of Minnesota, and the North American Neuroendocrine Tumor Society.

Course Directors

Emil Lou, MD, Ph.D, University of Minnesota; and Thor Halfdanarson, MD, Mayo Clinic


Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years there was great variability in terms of treatment. The diagnosis, treatment and management of NETs are time consuming, complex and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
  • Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
  • Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
  • Recognize the clinical features associated with carcinoid syndrome
  • Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
  • Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors



7:30-8:00       Registration & Breakfast

8:00-8:10       Welcome and Opening Remarks - Emil Lou, MD, Ph.D, University of Minnesota; and Thor Halfdanarson, MD, Mayo Clinic

8:10-9:30       Overview of Neuroendocrine Tumors

  • Background, Biology, Epidemiology, Symptoms, Biochemical Diagnosis – Emil Lou, MD, Ph.D University of Minnesota
  • Pathology of NETs: General Features, Classification, Grade, Staging, Sites – Rondell Graham, MD, Mayo ClinicImaging Modalities for Diagnosis and Follow-up: Anatomic and Functional Imaging and/or the Role of Somatostatin Receptor Imaging in Diagnosis and Follow Up – Tuba Kendi, MD, Mayo Clinic
  • Endoscopic Diagnosis and Management of NETs – Shawn Mallery, MD, University of Minnesota

9:30-10:45     Surgical Treatment of NETs

  • Intraoperative Management: Octreotide and Carcinoid Crisis – James Howe, MD, University of Iowa
  • Surgical Principles in SBNETs: Primary Tumor Management, Nodes, Metastases – James Howe, MD, University of Iowa
  • Surgical Principles in PNETs – Eric Jensen, MD, University of Minnesota
  • Surgery for Gastric, Duodenal, and Colorectal NETs – Eric Jensen, MD, University of Minnesota
  • Principles of Hepatic Cytoreduction – Rory Smoot, MD, Mayo Clinic
  • Panel: Question and Answer

10:45-11:00   Break

11:00-11:40   Medical Management of NETs

  • Overview of Agents Used for Tumor Control and Relevant Clinical Trials – Thor Halfdanarson, MD, Mayo Clinic
  • Treatment of Progressive and Poorly-differentiated NETs – Thor Halfdanarson, MD, Mayo Clinic

11:40-12:00   Radiology Management of NET

  • Imaging Modalities and Interventional Management of NET – Donna D’Souza, MD, University of Minnesota

12:00-1:00     Lunch

1:00-2:00       Peptide Receptor Radionuclide Therapy (PRRT)

  • PRRT: Background, Published Results, Patient Selection Details, Sequencing of Therapy, Future Directions – Jonathan Strosberg, MD, Moffitt Cancer Center
  • Pharmacology of Neuroendocrine Tumor Management – Andy Kurtzweil, PharmD, University of Minnesota
  • Panel: Question and Answer

2:00-3:30       Additional Important Topics in NETs

  • Hereditary Syndromes with NETs: MEN1/2, VHL Pheochromocytoma/Paraganglioma – Mark Lewis, MD, Intermountain Medical Oncology
  • Pulmonary NETs: Clinical Features, Medical and Surgical – Kostas Leventakos, MD, Mayo Clinic
  • Carcinoid Heart Disease – Heidi Connolly, MD, Mayo Clinic
  • Hormonal Syndromes in NETs, Functional PNETs – Timothy Hobday, MD, Mayo Clinic
  • Symptom Control in NETs – Timothy Hobday, MD Mayo Clinic

3:30-4:20       Case Presentations and Multidisciplinary Tumor Board

4:20                 Adjourn





In support of improving patient care, this activity is planned and implemented by Mayo Clinic College of Medicine and Science and North American Neuroendocrine Tumor Society (NANETS). Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



Credit Statement(s)


Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In-person registration available onsite on day of program and will be accommodated on a space-available basis

Registration fee:


$65 - MD, PharmD, Doctoral Level 
$35 - Allied Health
Complimentary - Student/Fellow/Resident


$95 - MD, PharmD, Doctoral Level 
$50 - Allied Health
Complimentary - Student/Fellow/Resident

Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before June 23, 2019. On or after June 24, 2019, no refund will be made.

Mayo Clinic, The University of Minnesota, and the North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is cancelled, liability is limited to registration fee.


Please contact us with any questions.